ABOUT THIS EPISODE
In this episode, Brendan McGrath shares his story of him being the first employee of WuXi Biologics in Ireland and how he helped turn an empty site into a 46,000 m² biologics facility in Dundalk.
He shares the greenfield risk he took, building through COVID and Brexit with 1,800 workers on site, and where automation, predictive data and sustainability are taking pharma manufacturing next.
Contact us at: pharmaconversationspodcast@gmail.com
This episode is sponsored by Molnlycke.
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of Pharma Conversations Podcast.
OTHER EPISODES IN THIS PODCAST
In this episode, Jim Polarine from STERIS breaks down how Annex 1 is reshaping contamination control strategy world wide covering CCS design, risk‑based decision making, residue management, gowning, environmental monitoring, and material transfer pitfalls like cart wheels. He contrasts Europe and t…
In this episode of Pharma Conversations, we sit down with Melanie Adams, Associate Director, Knowledge Management at MSD, to unpack what knowledge management really is and how it can be embedded into everyday ways of working.
Melanie shares practical strategies for capturing tacit knowledge (incl…
In this episode of Pharma Conversations, Laura Brennan Director of Technical Consulting at Ecolab breaks down the science and regulation behind disinfectant rotation in pharma cleanrooms, from the EU GMP Annex 1 and the FDA expectations to what actually works in practice.
She shares new multi-sit…
In this episode Craig Jacobs, Quality Culture Momentum Specialist of Affirm8 Quality Consultancy, unpacks what “quality culture” truly means in life sciences organizations. He explains that real quality shows up when no one is watching on the night shift, in audits, and in everyday process executio…
In this episode, tech transfer expert and lecturer Joe Brady explains why most projects are “already late on day one” and unpacks the real causes of delay across the product lifecycle, from stability studies and PPQ batches to warehouses, materials, and analytical methods. He contrasts innovator to…
Disclaimer: The podcast and artwork embedded on this page are from Pharma Conversations Podcast, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
